Lymphoma FAQ
Lymphoma FAQ
The questions on this page are the ones patients ask once the medical decisions are clearer — what treatment will cost, how long they will be away from home, which medicines can actually be given here, and what happens when they go back. They are answered separately from the medical pages on purpose, because they are practical rather than clinical, and because planning around them is what makes the treatment itself easier to complete.
What treatment costs
Treatment in China typically costs 30% to 50% of the equivalent in Europe or the United States. The comparison is a range across our network rather than a quoted price for any individual case, and the total depends on which part of the pathway you need:
- Diagnosis and pathology review — imaging, the biopsy procedure and the immunophenotyping panel, which is comparatively inexpensive but is the step everything else depends on.
- Immunochemotherapy — given in cycles over months, so the cost accumulates with the number of cycles rather than being concentrated in one admission; the antibody component is the largest part of the drug cost.
- Radiotherapy — a course delivered as daily outpatient treatment, priced by the course rather than by the session count in most cases.
- Cell therapy and transplant — the largest single components, because they require a period of inpatient monitoring, intensive care support if needed, and follow-up after discharge.
- Supportive care — antivirals, growth factor injections, anti-infective treatment and transfusions, which are individually modest and collectively a real part of the bill in prolonged treatment.
Two things are worth confirming early. First, which drugs in the recommended regimen are covered by insurance and which are not — in lymphoma the expensive items are usually the antibodies and the targeted agents, and policies differ widely in how they treat them. Second, the total is not only the hospital bill: accommodation for a companion, the number of journeys and the length of stay are all real costs, which is why the next section is worth reading alongside this one. The itemised estimate is drawn up from your own records rather than issued as a generic list.
How long you will need to stay
The length of a stay in China is determined by the regimen rather than by the diagnosis, and the difference between routes is substantial:
- Diagnosis and pathology — usually one to two weeks, since the biopsy and the immunophenotyping panel need time to be reported.
- Immunochemotherapy cycles — each cycle typically involves a short admission of a few days, with two to three weeks between cycles; the full course therefore spans three to six months and can often be continued partly at home.
- Radiotherapy — daily outpatient treatment over several weeks, without admission in most cases.
- Cell therapy — several weeks in total, including collection, the lymphodepleting treatment, the infusion and a period of close monitoring, which cannot be shortened.
- Autologous transplant — a period of inpatient care measured in weeks, followed by outpatient monitoring before travel.
The practical conclusion is that lymphoma treatment is usually delivered in stages rather than as one long stay, and that changes how travel is planned. The flight home should not be pinned to the date a cycle ends, because blood counts recover on their own schedule and a few days' delay is common. For treatment that runs over months, many patients arrange accommodation near the hospital and travel home between cycles. Ask for the written treatment calendar at the outset — the number of cycles, the intervals between them, and the imaging that falls between cycles — because it is that document which makes the travel arrangements possible.
Which medicines are available
Most medicines used in lymphoma internationally are available in our network, and the ones that matter most are these:
- Antibodies against CD20 — rituximab and obinutuzumab, the backbone of treatment for nearly every B-cell lymphoma.
- Combination chemotherapy — the regimens used for Hodgkin lymphoma and for aggressive B-cell lymphoma, with the same drugs and doses used internationally.
- Antibody-drug conjugates — including agents directed at CD30 and at CD79b, used in Hodgkin lymphoma and in first-line treatment for some aggressive B-cell lymphomas.
- Immune checkpoint inhibitors — directed at PD-1, which are unusually active in Hodgkin lymphoma.
- Bispecific antibodies — which redirect T cells to the lymphoma, used in relapsed B-cell disease.
- Bruton tyrosine kinase inhibitors — used in mantle cell lymphoma and in some indolent subtypes.
- CAR T-cell therapy — engineered cells directed at CD19, for relapsed or refractory B-cell lymphoma.
The availability of a particular drug depends on the hospital and on the indication, and it should be confirmed in writing in the plan rather than assumed. Two questions are worth asking explicitly. First, whether the exact drug named in the regimen is available here, and if not, whether there is an equivalent alternative. Second, what the supply position is for that product — some of the advanced therapies are made to order. For drugs approved internationally but not yet available in China, the treating team can sometimes suggest a workable alternative; the earlier the question is asked, the less effect it has on treatment.
Sending records and receiving a written opinion
The most useful thing a patient can send is not a summary but the original documents, because lymphoma decisions depend on details that summaries omit:
- The biopsy report in full, including the immunophenotyping panel and any molecular results — or better, the pathology block or slides themselves, which allow the diagnosis to be reviewed directly.
- The imaging as files — PET-CT and CT on disc or by transfer, rather than the report alone, since the response assessment depends on comparing the images themselves.
- The treatment history — which regimen, how many cycles, the dates given, the dose reductions if any, and the response at each assessment.
- Recent blood tests — blood count, liver and kidney function, LDH, and hepatitis and HIV status where known.
Material in English is reviewed directly; material in other languages is translated by our team. What is missing — most often the full immunophenotyping panel, or a report without the images — is stated explicitly, because those are the gaps that stop the subtype being confirmed and the plan being given with confidence. The written assessment is issued within 48 hours of the file being complete; the clock starts when the file is complete, not when the first document arrives.
Insurance and payment
Coverage for lymphoma treatment varies more than for most conditions, because so much of the cost sits in drugs rather than in procedures:
- Check whether the policy covers treatment outside your country of residence before assuming it does, and whether prior authorisation is required.
- Check the drug coverage specifically, particularly for antibodies, antibody-drug conjugates and cell therapy, which are often treated differently from inpatient care.
- Ask whether direct billing is available for your insurer, since paying and reclaiming is a different financial exercise from direct settlement.
- Request the documentation the insurer requires at the outset — a treatment plan, a cost estimate and clinical justification are usually needed, and they take time to assemble.
Two things are worth doing early rather than late. Authorisation for a high-cost drug or for cell therapy is the step that most often delays treatment, so starting it while the plan is being finalised can save several weeks. And because lymphoma treatment frequently runs over months, a policy with a per-item or an annual cap should be measured against the whole course rather than the first cycle. Our international patient team can supply the documents an insurer asks for; the earlier this begins, the less it interferes with the treatment itself.
After treatment, and back home
Lymphoma treatment crosses borders in a way that makes written handover more important than in most conditions:
- A written summary of the treatment actually given — drug names, cumulative doses, the number of cycles, and the response at the end-of-treatment assessment.
- A follow-up schedule with defined intervals — when the next scan or blood test is due, and how the intervals lengthen over time.
- Prophylaxis that continues — antivirals, vaccinations that are due, and any treatment that is being continued.
- Awareness of the late effects to watch for — cardiac symptoms after an anthracycline, thyroid dysfunction after neck radiotherapy, and any new persistent node or symptom.
- A named contact, for questions between visits and for arranging a video review of results taken elsewhere.
Flying after treatment is subject to a fitness-to-fly assessment; after cell therapy or a transplant the interval is longer and varies between individuals, so the return journey should not be pinned to the discharge date. And because follow-up often continues for years, most patients split it between home and here — an arrangement best agreed before the first trip rather than after it, because the real difficulty lies in transferring images and reports rather than in making the decision.
Eating and daily life during treatment
No diet treats lymphoma, and treatments marketed as dietary cures should be regarded with caution. What nutrition can legitimately do is support you through treatment, and the guidance is specific to the regimen:
- Food safety matters more than food choice. During chemotherapy the immune response is reduced, so avoiding unpasteurised dairy, raw or undercooked meat, eggs and seafood, and unwashed produce is a concrete protective measure.
- Adequate protein and calories to maintain weight, since weight loss during treatment is common and affects how well people tolerate the next cycle.
- Managing nausea and taste changes, which are among the most common side effects of the regimens used here; anti-sickness treatment should be adjusted rather than endured.
- Fluids during treatment, particularly when tumour lysis protection requires a high intake at the start of a cycle.
- Neutropenic precautions at home — avoiding crowded settings during the lowest point of the blood count, and reporting a fever immediately rather than monitoring it.
- Supplements — discussed with the team first, because some interact with treatment and some are marketed without evidence of benefit.
One point needs emphasis, because it is the one that turns into an emergency. In a patient with a low white cell count, a fever is not something to watch overnight — it is a signal to contact the treating team immediately and, in most cases, to be seen the same day. It is one of the few situations in lymphoma care where acting promptly genuinely changes the outcome, and it is the symptom patients most often leave until the next morning.